BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Stock Report

Market Cap: US$1.6b

BioCryst Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

BioCryst Pharmaceuticals's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 45.7% per year.

Key information

-8.0%

Earnings growth rate

0.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate45.7%
Return on equityn/a
Net Margin-30.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 09

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29
Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

Oct 11

BioCryst Pharmaceuticals promotes Sheridan to development chief

Sep 14

BioCryst wins FDA’s Orphan Drug status for bone disorder therapy

Aug 31

BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M

Aug 25

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

Revenue & Expenses Breakdown

How BioCryst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:BCRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24413-1242500
30 Jun 24382-1462350
31 Mar 24355-2092250
31 Dec 23331-2272140
30 Sep 23318-2362000
30 Jun 23307-2431860
31 Mar 23290-2261730
31 Dec 22271-2471590
30 Sep 22238-1931520
30 Jun 22204-2101430
31 Mar 22188-1941310
31 Dec 21157-1841190
30 Sep 21114-227970
30 Jun 2179-214870
31 Mar 2132-209740
31 Dec 2018-183630
30 Sep 2054-125520
30 Jun 2049-116470
31 Mar 2048-115420
31 Dec 1949-109370
30 Sep 1912-134310
30 Jun 1912-126270
31 Mar 1923-107330
31 Dec 1821-101300
30 Sep 1822-93300
30 Jun 1829-79250
31 Mar 1820-77140
31 Dec 1725-66140
30 Sep 1730-51120
30 Jun 1729-47110
31 Mar 1731-47110
31 Dec 1626-55110
30 Sep 1622-69110
30 Jun 1625-72110
31 Mar 1646-51120
31 Dec 1548-43130
30 Sep 1549-37120
30 Jun 1541-31110
31 Mar 1517-50100
31 Dec 1414-4570
30 Sep 1419-3970
30 Jun 1418-3870
31 Mar 1417-3660
31 Dec 1317-3060

Quality Earnings: BCRX is currently unprofitable.

Growing Profit Margin: BCRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies